Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2003-05-21
2004-11-02
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C530S350000, C435S007100
Reexamination Certificate
active
06811781
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to a composition and method for diagnosing auto-immune hepatitis, which use an immune reaction to detect soluble liver antigen (“SLA”) auto-antibodies.
Auto-immune hepatitis (AIH) is a chronic inflammation of the liver that when left untreated leads to cirrhosis, but when treated has a very good prognosis. For this reason, a timely diagnosis is important. It is estimated that 5% of all patients in Western countries who have chronic hepatitis have AIH. At the present time, there is no specific diagnostic test for AIH. Rather the diagnosis for AIH is undertaken by a plurality of diagnosis, such as excluding viral hepatitis, recognizing [hyper] immunoglobulinaemia, recognizing the tissue type (HLA type), and detecting auto-antibodies.
Auto-antibodies are found in about 90% of patients with chronic hepatitis, and most of the detectable auto-antibodies are also present, at least in low titers, in other inflammations of the liver as well. In particular, these auto-antibodies are antibodies to nuclear antigens (ANA) and unstriated muscles (SMA), as well as the very rare antibodies to cytochrome p450 (LKM). SLA auto-antibodies were described for the first time in 1987 (Manns M. et al., Lancet 1987;1:292-4). Tests have shown that SLA auto-antibodies occur in about 25 to 30% of patients having AIH, but hardly ever occur in patients having other diseases, including other auto-immune diseases (Lohse A. W. et al., Z. Gastroenterol 1995;33:527-33). Detecting SLA auto-antibodies therefore provides a significant diagnostic procedure for recognizing AIH.
The present invention is directed to use and detection of SLA antigens, which are a prerequisite for developing a specific immunoassay for detecting SLA auto-antibodies in patients' sera. Previous methods known in the art could not detect such SLA auto-antibodies in patients' sera. Liver cytokeratins 8 and 18 were described in 1990 as target antigens of the SLA auto-antibodies (Journal of Hepatology, 1990; 11: 232 to 239), however, these findings were never confirmed, and were even refuted (Wies I. et al., Z. Gastroenterol. 1998;36:93).
SUMMARY OF THE INVENTION
The invention is directed to a composition for detecting the presence of SLA auto-antibodies in blood serum, said composition comprising an antigen that is recognized by SLA auto-antibodies. In particular the invention is directed to antigens having amino acid sequence SEQ ID NO:2, SEQ ID NO:4, or antigenic derivatives thereof, or encoded by DNA having DNA sequence SEQ ID NO:1, SEQ ID NO:3, or antigenic derivatives thereof. Another embodiment of the invention is a purified protein or polypeptide recognized by SLA auto-antibodies. In a preferred embodiment of the invention the purified protein has the amino acid sequence SEQ ID NO:2, SEQ ID NO:4, or antigenic derivatives thereof, or encoded by DNA having DNA sequence SEQ ID NO: 1, SEQ ID NO:3, or antigenic derivatives thereof, or is a fusion protein containing either SEQ ID NO:2, SEQ ID NO:4, or antigenic derivatives thereof, or encoded by DNA having DNA sequence SEQ ID NO:1, SEQ ID NO:3, or antigenic derivatives thereof. In another aspect of the invention, there is disclosed a cDNA having a nucleotide sequence that codes for an antigen recognized by SLA auto-antibodies in blood serum. In a preferred embodiment of this aspect of the invention the cDNA codes for an antigen having the amino acid sequence SEQ ID NO:2, SEQ ID NO:4, or antigenic derivatives thereof, or has DNA sequence SEQ ID NO:1, SEQ ID NO:3, or antigenic derivatives thereof.
Another aspect of the invention is directed to a method of detecting the presence of SLA auto-antibodies in a blood sample by binding the composition of the invention to a matrix, detecting the binding of SLA auto-antibodies bound to the antigens in the composition, and correlating such binding to the presence of SLA auto-antibodies in the sample. Examples of suitable methods in which the present compositions can be used to detect SLA auto-antibodies in blood include immunoassays such as, but not limited to, radioimmunoassay, chemiluminescence, immunoassay, immunoblot assay, enzyme assay and inhibition immunoassay.
REFERENCES:
patent: 5196319 (1993-03-01), Coppel et al.
patent: 5284750 (1994-02-01), Silvestrini et al.
patent: 5457029 (1995-10-01), Coppel et al.
patent: 5741654 (1998-04-01), Michel et al.
patent: 5766867 (1998-06-01), Mishiro et al.
patent: 5830667 (1998-11-01), Alvarez
patent: 5830675 (1998-11-01), Targan et al.
patent: 5891436 (1999-04-01), Coppel et al.
NCBI Protein Accession CAB89517, Weis et al., SLA/LP autoantigen [Home sapiens].*
Shelton et al., Clinical Immunology and Immunopathology, vol. 28 No. 1, pp. 135-141 (Jul. 1983).*
Meyer Zum Büschenfelde et al., Clinical and Experimental Immunology vol. 10 No. 1. pp. 89-102 (1972).*
E. Ballot, et al.: “Antibodies To Soluble Liver Antigen In Auto-Immune Hepatitis Additional Oor Subtype Characteristic Marker”, Hepatology, vol. 28, No. 4, pp. 1543-1544, Meeting Abstract (Oct. 1998).
Weis I. Henniger, et al. “Cloning Of The Target-Antigen Of Antibodies To Soluble Liver Antigen: Identification Of A Novel 50 kDa Protein With Two Splice-Variants”, Hepatology, vol. 28, No. 4, pp. 112, Meeting Abstract (Oct. 1998).
T. Ando, et al.: “Determination Of Autoantibodies To Soluble Liver Antigen In Japanese Patients With Autoimmune Hepatitis”, Hepatology, vol. 26, No. 4, pp. 1378, Meeting Abstract (Oct. 1997).
R. Gruber, et al.: “Detection Of Autoantibodies Against M2, LKM-1, And SLA In Liver Diseases By Standardized Uniform ELISA-Techniques”, Journal of Clinical Laboratory Analysis, vol. 8, pp. 284-292 (1994).
Albert J. Czaja, et al.: “Antibodies To Soluble Liver Antigen, P450IID6, And Mitochondrial Complexes In Chronic Hepatitis”, Gastroenterology, vol. 105, No. 25, pp. 1522-1528 (1993).
D. F. Chen, et al.: “SLA Positive Autoimmune Hepatitis Is Strongly Associated With HLA DR3”, Human Immunology, Abstract, vol. 47, No. 1-2, p. P156 (1996).
A. Czaja, et al.: “Antigen-Specific Autoantibodies In Chronic Active Hepatitis: Valid Bases For Diagnostic Distinctions?”, Hepatology, Meeting Abstract, vol. 16, No. 2, p. 75 (1992).
Michael P. Manns, “Cytoplasmic Autoantigens In Autoimmune Hepatitis: Molecular Analysis And Clinical Relevance”, Seminars in Liver Disease, vol. 11, No. 3, pp. 205-214 (Aug. 1991).
M. Manns, et al.: “Characterisation Of A New Subgroup Of Autoimmune Chronic Active Hepatitis By Autoantibodies Against A Soluble Liver Antigen”, The Lancet, pp. 292-294 (1987).
Mikio Nishioka, et al.: Antibodies To P450IID6, SLA, PDH-E2 And BEKD-E2 In Japanese Patients With Chronic Hepatitis, Journal of Gastroenterology and Hepatology, vol. 12, No. 12, pp. 862-868 (997).
T. Heintges, et al.: “Differentiation Between Autoimmune Hepatitis And Hepatitis C Virus Related Liver Disease”, Z. Gastroenterologie, 1993, Bd. 31, Nr. 5, S. 285-288.
Housel James
Kenyon & Kenyon
Lucas Zachariah
LandOfFree
Composition and method for diagnosing auto-immune hepatitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for diagnosing auto-immune hepatitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for diagnosing auto-immune hepatitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3311012